Skip to content

Clinical study on Linggui Bafa of the time-acupoints-space acupuncture in treating primary insomnia

Clinical study on Linggui Bafa of the time-acupoints-space acupuncture in treating primary insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005874
Enrollment
Unknown
Registered
2022-04-17
Start date
2021-02-26
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Interventions

experimental group:Linggui Bafa of the time-acupoints-space acupuncture
control group:conventional acupuncture

Sponsors

Kunming Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The patient meets the diagnostic criteria of primary insomnia, with difficulty sleeping =3 nights a week and duration =1 month; (2) Pittsburgh Sleep Quality Index (PSQI) score > 7 points; (3) 18 to 70 years old; (4) Patients have a certain ability to read and understand words, and can cooperate with the scale evaluation involved in the study; (5) Patients are informed of the contents of this study and sign the informed consent form; (6) No other insomnia treatment was received within 2 weeks before participating in this study.

Exclusion criteria

Exclusion criteria: (1) Caused by systemic diseases such as pain, fever, cough, surgery, etc., and external environmental interference factors.; (2) Patients with severe mental disorders; (3) Patients with serious primary diseases such as cardiovascular disease, brain disease, lung disease, liver disease and kidney disease; (4) Patients with infectious diseases such as hepatitis B and tuberculosis; (5) Psychotropic drug abusers and alcoholics (6) Patients planning for pregnancy, pregnant or lactating women; (7) The acupuncture site of the patient has inflammation or wound infection; (8) The patient is participating in other clinical studies, which may interfere with the results of this trial.

Design outcomes

Primary

MeasureTime frame
clinical efficacy;PSQI scale;

Secondary

MeasureTime frame
Serum 5-HT;plasma E;SF-36 scale;HAMD scale;plasma DA;HAMA scale;plasma NE;ISI scale;

Countries

China

Contacts

Public ContactMiansheng Zhu
miansheng@wanadoo.fr13398853372

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026